[18F]FNA

[18F]FNA (fluorine-18-labeled nicotinic acid) is a radiopharmaceutical developed for positron emission tomography (PET) imaging of glioblastoma, the most malignant brain tumor in adults. It leverages Monocarboxylate Transporter 1 (MCT1), which is expressed on endothelial and glioblastoma cells, to cross the blood-brain barrier and accumulate in tumor tissue. The drug's interaction with the G protein-coupled receptor GPR109A, a high-affinity receptor for niacin (nicotinic acid), also plays a role in its tumor residence. This agent aims to improve glioblastoma imaging and potentially pave the way for niacin-derived theranostics.

Other names

fluorine-18-labeled nicotinic acidfluorine18-labeled nicotinic acidfluorine 18-labeled nicotinic acidfluorinated nicotinic acid